688073 Bide Pharmatech
- 47.20
- -0.65-1.36%
Bide Pharmatech News
Bide Pharmaceutical (688073) 2024 three-quarter report review: Overseas markets continue to gain strength, and the business trend is improving steadily
Bide Pharmaceutical (688073): Profitability continues to improve, and revenue grows steadily
Bide Pharmaceuticals (688073): Structural adjustment shows that it has broken out of a profit low
Bide Pharmaceutical (688073): Looking forward to continued strength in overseas markets
Bide Pharmaceutical (688073): Overseas contributions to core performance growth, short-term profits are under pressure
Bide Pharmaceutical (688073): Overseas advantages continue to be optimistic about improving quality and efficiency
Bide Pharmaceutical (688073): The quarterly business trend is improving, and we look forward to continued strength in overseas markets
Bide Pharmaceutical (688073): Quarterly operations tend to be steady and optimistic about the company's long-term development
Open Source Securities released a research report on April 26 stating that it gave Bide Pharmaceutical (688073.SH) a purchase rating. The main reasons for the rating include: 1) accelerating the global layout and continuing high growth in overseas busines
Bide Pharmaceutical (688073) Company Information Update Report: Steady growth in operating revenue awaits profit release in 2024
Bide Pharmaceutical (688073) Company Information Update Report: Steady Revenue Growth, Phased Pressure on Profit Side
Bide Pharmaceutical (688073): Short-term performance pressure is optimistic that overseas markets will continue to gain strength
Bide Pharmaceutical (688073): Short-term performance under pressure, “core competitiveness” lays the driving force for the company's long-term growth
Bide Pharmaceuticals (688073): Rapid growth in revenue, fluctuations in gross margin disrupt profits
Bide Pharmaceutical (688073) Company Brief Review Report: Q2 Performance Reaches New Heights, Continued Optimization of Management Efficiency
Bide Pharmaceutical (688073): Performance maintained strong growth and market share increased steadily
Bide Pharmaceutical (688073) 2023 Interim Report Review: Q2 Meets Expectations, Inventory Turnover Rate Has Increased Significantly
Bide Pharmaceutical (688073): Consolidate how fast it is to consolidate the advantages of the province and maintain rapid growth
Bide Pharmaceutical (688073): Continued high growth in performance highlights the company's α under pressure from industry demand
Bide Pharmaceutical (688073): Continued high performance growth, overseas market growth can be expected
No Data